Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells. (Q39632688)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21072520%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21072520%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21072520%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Li-Yuan Bai

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21072520%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Chang-Fang Chiu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21072520%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Zeng-Pang Chi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21072520%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Jing-Lan Hu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21072520%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Jing-Ru Weng

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21072520%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

12 November 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21072520%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21072520%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

68

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21072520%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21072520%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

489-496

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21072520%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00280-010-1501-z

16 January 2020

exact match

0 references

cites work

New drugs for myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

The potential role of epigenetic therapy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

The role of histone deacetylases (HDACs) in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

Prospects: histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

Vorinostat enhances the antimyeloma effects of melphalan and bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

Vorinostat in solid and hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

NF-kappa B as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1501-Z